HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects.

Abstract
Efalizumab was authorized to be put on the market in France starting July 21, 2005. Its efficacy and tolerance profile in plaque psoriasis at a dose of 1 mg kg(-1) weekly in a subcutaneous injection have been studied in phase III trials. At the current moment, more than 3,500 patients have been included in clinical trials. Flu-like symptoms (fever, chills, headaches, nausea, vomiting, myalgia) are the most frequent adverse events. On the skin, a localized papular rash or the aggravation of the psoriasis in an edematous or even pustular form are the two most regularly observed complications. At the biological level, hyperlymphocytosis and a temporary increase in alkaline phosphatases without clinical consequences are the most frequent anomalies. We report 2 adverse events under efalizumab that to our knowledge have never been described: a case of an eczematous rash and a case of thrombocytosis.
AuthorsD Firmin, A M Roguedas, G Lemasson, J F Abgrall, L Misery
JournalDermatology (Basel, Switzerland) (Dermatology) Vol. 217 Issue 3 Pg. 203-6 ( 2008) ISSN: 1421-9832 [Electronic] Switzerland
PMID18594143 (Publication Type: Case Reports, Journal Article)
CopyrightCopyright 2008 S. Karger AG, Basel.
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • efalizumab
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal (administration & dosage, adverse effects)
  • Antibodies, Monoclonal, Humanized
  • Eczema (chemically induced)
  • Female
  • Humans
  • Injections, Subcutaneous
  • Male
  • Psoriasis (drug therapy)
  • Thrombocytosis (chemically induced)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: